BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Down 94.1% in January

BriaCell Therapeutics Corp. (NASDAQ:BCTX) saw a significant decrease in short interest in January. As of January 31st, there was short interest totalling 94,800 shares, a decrease of 94.1% from the January 15th total of 1,620,000 shares. Approximately 2.8% of the shares of the stock are short sold. Based on an average daily volume of 346,800 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Trading of BriaCell Therapeutics

An institutional investor recently raised its position in BriaCell Therapeutics stock. Vontobel Holding Ltd. increased its position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 37.5% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 110,000 shares of the company’s stock after purchasing an additional 30,000 shares during the quarter. Vontobel Holding Ltd. owned 0.25% of BriaCell Therapeutics worth $62,000 as of its most recent filing with the SEC. 15.42% of the stock is owned by institutional investors.

BriaCell Therapeutics Price Performance

BCTX traded down $0.11 on Thursday, reaching $3.67. 23,581 shares of the company’s stock were exchanged, compared to its average volume of 642,514. The stock has a market cap of $10.83 million, a PE ratio of -0.28 and a beta of 1.59. BriaCell Therapeutics has a twelve month low of $3.33 and a twelve month high of $55.95. The stock’s fifty day moving average price is $7.62 and its 200-day moving average price is $10.07.

BriaCell Therapeutics (NASDAQ:BCTX) last issued its quarterly earnings data on Monday, December 16th. The company reported ($3.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($2.10). As a group, research analysts predict that BriaCell Therapeutics will post -2.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright boosted their price objective on BriaCell Therapeutics from $15.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, February 3rd.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.